European Early Access News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from European early access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In European Early Access Today - Breaking & Trending Today

Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES

Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome. ....

United States , Porter Novelli , Trish Mccall , Tevard Biosciences , Bradleys Galer , Brian Ritchie , Us Securities Exchange Commission , Lifesci Advisors , American Epilepsy Society , European Commission , Drug Administration , European Early Access Program , European Medicines Agency , Annual Meeting , Better Outcomes Through Diversity , Executive Vice President , Chief Medical Officer , Zogenix Newsroom , Treatment Improves Everyday Executive Functioning , Preschool Children With Dravet Syndrome , Analysis From , Significantly Reduces Day To Seizure Burden , Increasing Seizure Free Days , Time To Event Analysis , Echocardiographic Assessment , Dravet Syndrome Treated ,

Advicenne Reports its Full-Year Financial Results to December 31, 2020 and Confirms its 2021 Outlook

Advicenne Reports its Full-Year Financial Results to December 31, 2020 and Confirms its 2021 Outlook
Regulatory News:
Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC), a French company specialized in the development of therapeutic products adapted to children and adults for treating nephrological and neurological orphan diseases, today reported its 2020 financial results.
2020 HIGHLIGHTS
Scientific developments
On March 10, 2020, Advicenne was authorized to make ADV7103 available within the framework of a Temporary Authorization for Use (TAU) scheme established by France s National Agency of Medicine and Health Products Safety (
Agence nationale de sécurité du médicament et des produits de santé (ANSM)). This authorization allows the exceptional use of coated 8 mEq and 24 mEq granules in sachets for the treatment of distal renal tubular acidosis (dRTA) in France. Its prescription is reserved for physicians specializing in nephrology. ....

United States , France General , Hege Hellstrom , Nicolas Merigeau , Dusan Oresansky , Peter Meeus , Advicenne Euronext , Emmanuel Huynh , David Solomon , Health Products Safety Agence , French Financial Markets Authority Autorit , France National Agency Of Medicine , Advicenne Inc , Sales Of The Company , European Investment Bank , Financial Communications , Regulatory News , Temporary Authorization , National Agency , Health Products Safety , Medicinal Products , Human Use , European Medicines Agency , Chief Executive Officer , State Guaranteed Loans , European Marketing Approval ,